ADICET Bio, Inc.
adicetbio.comWhat Do They Do?
Develops ready-made engineered gamma delta T-cell therapy candidates for autoimmune diseases and cancer.
10-K for FY2025, filed Mar 12, 2026
Who Are Their Customers?
Biopharmaceutical collaborators license intellectual property and work with Adicet on research and development. Regeneron licensed worldwide rights to a product candidate and is responsible for its development, manufacturing and commercialization.
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 5, 2026
−$21.4MView ↗
- ▼ −32% (Loss)
- vs −$31.2M in Q2 FY2025
A broader therapeutic focus
The older report focused the platform and pipeline on cancer, including a lead candidate for B-cell lymphoma. The latest report centers prula-cel on autoimmune diseases while retaining cancer programs, including a candidate for prostate cancer.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 12, 2026
Who Do They Compete With?
Competes with Kite Pharma and Novartis
10-K for FY2025, filed Mar 12, 2026Autologous cell therapies, such as those developed by Kite Pharma and Novartis, have a number of limitations, including but not limited to…View ↗
Loading...
